Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
Organic & Biomolecular Chemistry
|
May 30, 2013
Synthesis of analogs of the radiation mitigator JP4-039 and visualization of BODIPY derivatives in mitochondria
Marie-Céline Frantz, Erin M Skoda, Joshua R Sacher, et al.
Bone Marrow Transplantation
|
February 1, 1993
A novel approach to immunomodulation of frozen human bone marrow with interleukin-2 for clinical application
B S Charak, E M Areman, S A Dickerson, et al.
Cancer Treatment Reports
|
April 1, 1986
Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial
M R Cooper, A Fefer, J Thompson, et al.
In Vivo (Athens, Greece)
|
January 9, 2017
Effectiveness of Analogs of the GS-Nitroxide, JP4-039, as Total Body Irradiation Mitigators
Michael W Epperly, Joshua R Sacher, Tanja Krainz, et al.
Investigational New Drugs
|
January 1, 1987
Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial
M R Cooper, A Fefer, J Thompson, et al.
Cancer Letters
|
March 4, 2022
SS-4 is a highly selective small molecule inhibitor of STAT3 tyrosine phosphorylation that potently inhibits GBM tumorigenesis in vitro and in vivo
Yinan Wang, Chuanhe Yang, Michelle M Sims, et al.
Journal of Molecular and Cellular Cardiology
|
December 3, 2014
Mitochondria-targeted ROS scavenger improves post-ischemic recovery of cardiac function and attenuates mitochondrial abnormalities in aged rats
Nelson Escobales, Rebeca E Nuñez, Sehwan Jang, et al.
Seminars in Hematology
|
July 1, 1992
Continuous infusion intravenous immunoglobulin is associated with a reduced incidence of infection and achieves higher serum immunoglobulin G levels than intermittent infusion following bone marrow transplantation
T R Spitzer, M Cottler-Fox, P Sullivan, et al.
British Journal of Haematology
|
August 1, 1994
Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy
L T Goodnough, T H Price, C A Parvin, et al.
Transfusion
|
January 1, 1994
A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy
L T Goodnough, T H Price, K D Friedman, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
Organic & Biomolecular Chemistry
|
May 30, 2013
Synthesis of analogs of the radiation mitigator JP4-039 and visualization of BODIPY derivatives in mitochondria
Marie-Céline Frantz, Erin M Skoda, Joshua R Sacher, et al.
Bone Marrow Transplantation
|
February 1, 1993
A novel approach to immunomodulation of frozen human bone marrow with interleukin-2 for clinical application
B S Charak, E M Areman, S A Dickerson, et al.
Cancer Treatment Reports
|
April 1, 1986
Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial
M R Cooper, A Fefer, J Thompson, et al.
In Vivo (Athens, Greece)
|
January 9, 2017
Effectiveness of Analogs of the GS-Nitroxide, JP4-039, as Total Body Irradiation Mitigators
Michael W Epperly, Joshua R Sacher, Tanja Krainz, et al.
Investigational New Drugs
|
January 1, 1987
Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial
M R Cooper, A Fefer, J Thompson, et al.
Cancer Letters
|
March 4, 2022
SS-4 is a highly selective small molecule inhibitor of STAT3 tyrosine phosphorylation that potently inhibits GBM tumorigenesis in vitro and in vivo
Yinan Wang, Chuanhe Yang, Michelle M Sims, et al.
Journal of Molecular and Cellular Cardiology
|
December 3, 2014
Mitochondria-targeted ROS scavenger improves post-ischemic recovery of cardiac function and attenuates mitochondrial abnormalities in aged rats
Nelson Escobales, Rebeca E Nuñez, Sehwan Jang, et al.
Seminars in Hematology
|
July 1, 1992
Continuous infusion intravenous immunoglobulin is associated with a reduced incidence of infection and achieves higher serum immunoglobulin G levels than intermittent infusion following bone marrow transplantation
T R Spitzer, M Cottler-Fox, P Sullivan, et al.
British Journal of Haematology
|
August 1, 1994
Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy
L T Goodnough, T H Price, C A Parvin, et al.
Transfusion
|
January 1, 1994
A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy
L T Goodnough, T H Price, K D Friedman, et al.
Page
of 5